What is LOPJLB’s current signal on ARVN?

LOPJLB’s latest quantitative signal on Arvinas, Inc. (ARVN) is SELL in a CRISIS regime. Signals are updated daily.

What market regime is ARVN in?

Arvinas, Inc. (ARVN) is currently classified in the CRISIS HMM market regime on LOPJLB.

What does Arvinas, Inc. (ARVN) do?

Arvinas, Inc. is a biopharmaceutical company in the clinical development stage, dedicated to identifying, advancing, and marketing innovative therapies designed to eliminate disease-causing proteins. The company's pipeline features several promising candidates. These include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader, currently in Phase I clinical trials, which s…

Arvinas, Inc. (ARVN)

COMPARE

Healthcare · Biotechnology · NASDAQ · US

$6.84-8.19%Close

SELLCRISIS · day 1

Company news

zacks.com · 17h ago

Reasons Why Investors Should Consider Betting on Arvinas Stock

globenewswire.com · 7d ago

Arvinas Shares Novel Oculomotor and Biomarker Data from Phase 1 Clinical Trial of ARV-102 in Patients with Parkinson's Disease

globenewswire.com · 13d ago

Arvinas to Present Novel Biomarker Data from the Phase 1 Clinical Trial for ARV-102, a PROTAC LRRK2 Degrader, at the 2026 International Congress of Parkinson's Disease and Movement Disorders®

globenewswire.com · 15d ago

Arvinas Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

globenewswire.com · 16d ago

Arvinas Announces First Patient Dosed in Phase 1/2 Clinical Trial of ARV-6723, the Company's First Immuno-Oncology Candidate

seekingalpha.com · 28d ago

Arvinas, Inc. (ARVN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

globenewswire.com · 41d ago

Arvinas to Participate in Upcoming Investor Conferences

globenewswire.com · 43d ago

Arvinas Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

defenseworld.net · 45d ago

Connor Clark & Lunn Investment Management Ltd. Invests $1.39 Million in Arvinas, Inc. $ARVN

seekingalpha.com · 47d ago

Arvinas: Veppanu Approval Underlines Degrader Platform Promise - I'm Bullish

zacks.com · 69d ago

Arvinas (ARVN) Upgraded to Strong Buy: Here's What You Should Know

defenseworld.net · 69d ago

Arvinas Q2 Earnings Call Highlights

seekingalpha.com · 71d ago

Arvinas, Inc. (ARVN) Q2 2026 Earnings Call Transcript

marketbeat.com · 71d ago

Arvinas Q2 Earnings Call Highlights

zacks.com · 71d ago

Arvinas, Inc. (ARVN) Beats Q2 Earnings and Revenue Estimates

globenewswire.com · 71d ago

Arvinas Reports Second Quarter 2026 Financial Results and Provides Corporate Update

globenewswire.com · 78d ago

Arvinas to Report Second Quarter 2026 Financial Results on August 4, 2026

Market news & ticker search · RSS for ARVN

FAQ

What is LOPJLB’s current signal on ARVN?: LOPJLB’s latest quantitative signal on Arvinas, Inc. (ARVN) is SELL in a CRISIS regime. Signals are updated daily.
What market regime is ARVN in?: Arvinas, Inc. (ARVN) is currently classified in the CRISIS HMM market regime on LOPJLB.
What does Arvinas, Inc. (ARVN) do?: Arvinas, Inc. is a biopharmaceutical company in the clinical development stage, dedicated to identifying, advancing, and marketing innovative therapies designed to eliminate disease-causing proteins. The company's pipeline features several promising candidates. These include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader, currently in Phase I clinical trials, which s…

Arvinas, Inc. (ARVN)

Key stats

Industry peers

Prediction markets

Company news

FAQ